Cargando…

The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G(2)/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells

Alisertib (ALS) is an investigational potent Aurora A kinase inhibitor currently undergoing clinical trials for the treatment of hematological and non-hematological malignancies. However, its antitumor activity has not been tested in human breast cancer. This study aimed to investigate the effect of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Jin-Ping, Yang, Yin-Xue, Liu, Qi-Lun, Pan, Shu-Ting, He, Zhi-Xu, Zhang, Xueji, Yang, Tianxin, Chen, Xiao-Wu, Wang, Dong, Qiu, Jia-Xuan, Zhou, Shu-Feng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4365748/ https://www.ncbi.nlm.nih.gov/pubmed/25834401 http://dx.doi.org/10.2147/DDDT.S75378

Ejemplares similares

MLN8054 and Alisertib (MLN8237): Discovery of Selective Oral Aurora A Inhibitors
por: Sells, Todd B., et al.
Publicado: (2015)

Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway
por: Niu, Ning-Kui, et al.
Publicado: (2015)

A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma
por: Gay, Carl M., et al.
Publicado: (2020)

Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors
por: Falchook, Gerald S., et al.
Publicado: (2015)

An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes
por: Goldberg, Stuart L., et al.
Publicado: (2014)

MLN-8237: A dual inhibitor of aurora A and B in soft tissue sarcomas
por: Nair, Jayasree S., et al.
Publicado: (2016)

Development of an intravaginal ring for the topical delivery of Aurora kinase A inhibitor, MLN8237
por: Tayyar, Yaman, et al.
Publicado: (2019)

Alisertib promotes apoptosis and autophagy in melanoma through p38 MAPK-mediated aurora a signaling
por: Shang, Yuan-Yuan, et al.
Publicado: (2017)

Plumbagin induces G(2)/M arrest, apoptosis, and autophagy via p38 MAPK- and PI3K/Akt/mTOR-mediated pathways in human tongue squamous cell carcinoma cells
por: Pan, Shu-Ting, et al.
Publicado: (2015)

A Novel Aurora-A Inhibitor (MLN8237) Synergistically Enhances the Antitumor Activity of Sorafenib in Hepatocellular Carcinoma
por: Zhang, Kai, et al.
Publicado: (2018)

Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer
por: Carol, Hernan, et al.
Publicado: (2011)

The Aurora-A inhibitor MLN8237 affects multiple mitotic processes and induces dose-dependent mitotic abnormalities and aneuploidy
por: Asteriti, Italia Anna, et al.
Publicado: (2014)

The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib
por: Kelly, Kevin R, et al.
Publicado: (2011)

Silencing of AURKA augments the antitumor efficacy of the AURKA inhibitor MLN8237 on neuroblastoma cells
por: Yang, Yan, et al.
Publicado: (2020)

Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells
por: Wang, Feng, et al.
Publicado: (2015)

Alisertib, an Aurora kinase A inhibitor, induces apoptosis and autophagy but inhibits epithelial to mesenchymal transition in human epithelial ovarian cancer cells
por: Ding, Yong-Hui, et al.
Publicado: (2015)

Targeting mTOR with MLN0128 Overcomes Rapamycin and Chemoresistant Primary Effusion Lymphoma
por: Caro-Vegas, Carolina, et al.
Publicado: (2019)

Phase I study of MLN8237—investigational Aurora A kinase inhibitor—in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia
por: Kelly, Kevin R., et al.
Publicado: (2013)

Inhibition of mitotic Aurora kinase A by alisertib induces apoptosis and autophagy of human gastric cancer AGS and NCI-N78 cells
por: Yuan, Chun-Xiu, et al.
Publicado: (2015)

Dual mTOR inhibitor MLN0128 suppresses Merkel cell carcinoma (MCC) xenograft tumor growth
por: Kannan, Aarthi, et al.
Publicado: (2015)

ABCG2 impairs the activity of the aurora kinase inhibitor tozasertib but not of alisertib
por: Michaelis, Martin, et al.
Publicado: (2015)

Essential Roles of mTOR/Akt Pathway in Aurora-A Cell Transformation
por: Taga, Makoto, et al.
Publicado: (2009)

Aurora-A/ERK1/2/mTOR axis promotes tumor progression in triple-negative breast cancer and dual-targeting Aurora-A/mTOR shows synthetic lethality
por: Zhang, Wenfeng, et al.
Publicado: (2019)

Domain-specific interactions between MLN8237 and human serum albumin estimated by STD and WaterLOGSY NMR, ITC, spectroscopic, and docking techniques
por: Yang, Hongqin, et al.
Publicado: (2017)

Aurora-A Induces Chemoresistance Through Activation of the AKT/mTOR Pathway in Endometrial Cancer
por: Wu, Jun, et al.
Publicado: (2019)

Cisplatin‐resistant cancer cells are sensitive to Aurora kinase A inhibition by alisertib
por: Wang, Lihong, et al.
Publicado: (2017)

mTOR and MAPK: from localized translation control to epilepsy
por: Pernice, Helena F., et al.
Publicado: (2016)

Induction of apoptosis and autophagy via sirtuin1- and PI3K/Akt/mTOR-mediated pathways by plumbagin in human prostate cancer cells
por: Zhou, Zhi-Wei, et al.
Publicado: (2015)

Autophagy Inhibits Inflammation via Down-Regulation of p38 MAPK/mTOR Signaling Cascade in Endothelial Cells
por: Zhou, Ling, et al.
Publicado: (2023)

Aurora-B knockdown inhibits osteosarcoma metastasis by inducing autophagy via the mTOR/ULK1 pathway
por: Wu, Xin, et al.
Publicado: (2020)

Biphasic regulation of osteoblast development via the ERK MAPK–mTOR pathway
por: Kim, Jung-Min, et al.
Publicado: (2022)

mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012)

Disruption of mTOR and MAPK pathways correlates with severity in idiopathic autism
por: Rosina, Eleonora, et al.
Publicado: (2019)

MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cells
por: Zeng, Zhihong, et al.
Publicado: (2016)

Mio depletion links mTOR regulation to Aurora A and Plk1 activation at mitotic centrosomes
por: Platani, Melpomeni, et al.
Publicado: (2015)

Myelination and mTOR
por: Figlia, Gianluca, et al.
Publicado: (2017)

Effect of alisertib, an investigational aurora a kinase inhibitor on the QTc interval in patients with advanced malignancies
por: Zhou, Xiaofei, et al.
Publicado: (2017)

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
por: Zou, Zhilin, et al.
Publicado: (2020)

Danusertib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR-mediated signaling pathway in human gastric cancer AGS and NCI-N78 cells
por: Yuan, Chun-Xiu, et al.
Publicado: (2015)

IL‐38 prevents induction of trained immunity by inhibition of mTOR signaling
por: de Graaf, Dennis M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dnqud53mc95918r4mdjml9unmm